Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
641-660 of 1,743 trials

Heart Procedure: Short vs. Long Antiplatelet Therapy

We are studying whether a shorter duration of antiplatelet therapy after a heart procedure is as safe and effective as the standard longer treatment. This trial is for patients who have had coronary angioplasty for blocked arteries.

Chronically Occluded Coronary Artery>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Dexamethasone for Severe Hospital-Acquired Pneumonia

We are studying whether dexamethasone can improve outcomes for critically ill patients with severe hospital-acquired pneumonia. This trial will also assess safety and how patients feel about the treatment.

Hospital-acquired Pneumonia>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Advanced Solid Tumors: RMC-6291 and RMC-6236 Combination Study

We are examining how well different doses of RMC-6291 and RMC-6236 are tolerated by people with advanced KRASG12C-mutated solid tumors. This study aims to gather important safety information about this treatment combination.

Non-Small Cell Lung CancerPancreatic AdenocarcinomaColorectal Cancer>2 yearsSafety phase (I)Oncology

Chronic Inflammatory and Fibrotic Diseases: 68Gallium-FAPI PET/CT Imaging Study

We are exploring how a new imaging method can help assess chronic inflammatory and fibrotic diseases. This study aims to understand the relationship between imaging results and disease severity, quality of life, and other health indicators.

Inflammatory Disorders>2 yearsEfficacy phase (II)No PlaceboInvestigational Medicines

Antiplatelet Therapy Duration After TAVI

We are studying whether a shorter 3-month antiplatelet therapy is as effective as the standard 12-month therapy after TAVI. The goal is to see if it reduces complications and bleeding risks.

Aortic Stenosis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

HER3-Targeted Imaging with Patritumab Deruxtecan

We are studying the best dose of a new imaging agent for patients with tumors that express HER3. This research aims to improve how we visualize and understand tumor response to treatment.

EGFR Mutation Positive Advanced Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOncology

Crohn's Disease: Obefazimod Study

We are testing a new medication, obefazimod, for people with moderately to severely active Crohn's disease who haven't responded to other treatments. The study aims to see if it is more effective and safe compared to a placebo.

Crohn's Disease>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Acute Mesenteric Ischemia: Oral Antibiotics Study

We are investigating whether oral antibiotics can help reduce serious complications in patients with acute mesenteric ischemia. This study compares the effects of antibiotics to a placebo to see if they improve patient outcomes.

Acute Mesenteric Ischemia>2 yearsConfirmation phase (III)Standard MedicinesCardiologyGastroenterology

Psoriatic Arthritis: Tapering Immunosuppressive Therapy

We are studying whether reducing immunosuppressive medication helps adults with psoriatic arthritis maintain stable disease activity. The trial also looks at the safety of this approach.

Psoriatic Arthritis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineRheumatology

Noncardiac Surgery: Noradrenaline Infusion Study

We are investigating if noradrenaline infusion is more effective than standard blood pressure management in preventing low blood pressure during noncardiac surgery. This study aims to improve patient safety and outcomes in the operating room.

Low Blood Pressure During Surgery>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyOtolaryngology

Ovarian Cancer: SALVOVAR Trial on Chemotherapy Regimens

We are studying whether a new weekly chemotherapy schedule improves outcomes for patients with poor prognostic ovarian cancer compared to the standard treatment. This trial aims to see if it helps with surgery success and overall survival.

Advanced Ovarian and Fallopian Tube Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Meniscal Loss: Spongioflex® Allografts Study

We are investigating whether sterile allogeneic spongioflex® allografts can improve knee function in patients with incomplete meniscal loss. The study will also assess safety and patient satisfaction over several years.

Meniscus Tear>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOrthopedics and Traumatology

Recurrent Glioblastoma: Ipilimumab and Nivolumab Treatment

We are testing a new combination of two immunotherapy drugs for patients with recurrent glioblastoma. The goal is to see if this approach improves treatment outcomes compared to standard options.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Urothelial Cancer: Sacituzumab Govitecan Study

We are investigating a new treatment for patients with advanced urothelial cancer that cannot be removed by surgery. The study aims to see how effective and safe this treatment is compared to existing options.

Urothelial Cancer of the Renal Pelvis>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineOncologyUrology

NBI-1076986: Safety and Effects in Healthy Adults

We are studying a new medication to see how safe it is and how the body reacts to it in healthy adults. This research helps us understand its potential for future use in patients.

Movement Disorders>2 yearsSafety phase (I)Neurology

Liver Tumors: Indocyanine Green for Better Detection

We are testing whether a dye can help surgeons find liver tumors more easily during surgery. This study aims to improve surgical outcomes and understand how the dye behaves in the liver.

Resectable Malignant Liver Tumor>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHepatologyOncology

Chronic Inflammatory Demyelinating Polyneuropathy: Riliprubart vs. IVIg

We are studying a new treatment called riliprubart to see if it works better than the standard IVIg therapy for people with chronic inflammatory demyelinating polyneuropathy. The trial will evaluate its effects on disability, fatigue, and overall quality of life.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesInternal MedicineNeurology

Relapsed/Refractory T-Cell Leukemia: CD7 CAR T-Cell Therapy

We are testing a new type of T-cell therapy for children and young adults with relapsed or refractory T-cell leukemia or lymphoma. The study aims to find a safe dose and see how well it works.

T-cell Acute Lymphoblastic Leukemia/Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Lung Cancer: ABP 234 vs. Keytruda

We are evaluating a new treatment for early-stage non-squamous non-small cell lung cancer to see how it compares to Keytruda after surgery and chemotherapy. This study aims to understand if the new drug works similarly in the body.

Early-stage Non-squamous Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)OncologyPulmonology

Renal Lifecycle Trial: Dapagliflozin for Severe Chronic Kidney Disease

We are studying whether dapagliflozin can improve kidney and heart health in patients with severe chronic kidney disease. This includes those on dialysis and kidney transplant recipients.

Healthy Participants>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCardiologyNephrology